{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:29:25Z","timestamp":1789784965731,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yunnan Orthopedics and Sports Rehabilitation Clinical Medicine Research Center","award":["No. 202102AA310068"],"award-info":[{"award-number":["No. 202102AA310068"]}]},{"name":"Yunnan Province Science and Technology Talent and Platform Program Project","award":["No. 202105AD160027"],"award-info":[{"award-number":["No. 202105AD160027"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072441"],"award-info":[{"award-number":["No. 82072441"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Outstanding Youth Fund Project","award":["No. 2022JJ10095"],"award-info":[{"award-number":["No. 2022JJ10095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>RING finger protein 43 (RNF43), an E3 ubiquitin ligase, is a homologous gene mutated in several cancers. However, the pan-cancer panoramic picture of RNF43 and its predictive value for tumor immune phenotypes and immunotherapeutic efficacy are still largely unclear. Our study aims to clarify the functions of RNF43 in predicting the prognosis, immune signature, and immunotherapeutic efficacy in pan-cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>By using RNA-seq, mutation, and clinical data from the TCGA database, the expression levels and prognostic significance of RNF43 in pan-cancer were analyzed. The genetic alteration characteristics of RNF43 were displayed by the cBioPortal database. Gene Set Enrichment Analysis (GSEA) was performed to investigate the potential biological functions and signaling pathways modulated by RNF43 in cancers. The relationship of RNF43 expression with immune cell infiltration, and immune modulators expression was interpreted by the ESTIMATE algorithm, CIBERSORT algorithm, and TISIDB database. The correlations between RNF43, microsatellite instability (MSI), and tumor mutation burden (TMB) were also investigated. Furthermore, the predictive value of RNF43 for immunotherapeutic efficacy and drug sensitivity was further illustrated. Besides, immunohistochemistry (IHC) was employed to validate the expression of the RNF43 in different cancer types by our clinical cohorts, including patients with lung cancer, sarcoma, breast cancer, and kidney renal clear cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results demonstrated that RNF43 was abnormally expressed in multiple cancers, and RNF43 is a critical prognosis-related factor in several cancers. RNF43 was frequently mutated in several cancers with a high frequency of 4%, and truncating mutation was the most frequent RNF43 mutation type. RNF43 expression was linked to the abundance of several immune cell types, including CD8+\u2009T cells, B cells, and macrophages within the tumor immune microenvironment. Furthermore, RNF43 expression was significantly correlated with the efficacy of anti-PD-1\/PD-L1 treatment, and it could predict the sensitivity of various anti-cancer drugs. Finally, IHC explored and validated the different expression levels of RNF43 in different cancers by our clinical samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results first present the expression pattern and the mutation signature of RNF43, highlighting that RNF43 is an important prognostic biomarker in pan-cancer. Furthermore, RNF43 seems to be a critical modulator in the tumor immune microenvironment and can function as a promising biomarker for predicting the immunotherapeutic efficacy of anti-PD-1\/PD-L1 treatment, and drug sensitivity in cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-023-01383-1","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:01:46Z","timestamp":1697500906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker"],"prefix":"10.1186","volume":"28","author":[{"given":"Yingting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"1383_CR2","doi-asserted-by":"crossref","first-page":"688215","DOI":"10.3389\/fimmu.2021.688215","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Du J, Liu C, Zeng H, Chen Y, Liu L, Wu D. A pan-cancer analysis of CD161, a potential new immune checkpoint. Front Immunol. 2021;12:688215.","journal-title":"Front Immunol"},{"key":"1383_CR3","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.7150\/thno.46176","volume":"10","author":"D Zeng","year":"2020","unstructured":"Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G, Huang Y, Wu J, Sun H, Wang M, Bin J, Liao Y, Li N, Shi M, Liao W. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020;10:7002\u201314.","journal-title":"Theranostics"},{"key":"1383_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10555-021-09967-1","volume":"40","author":"A Kumar","year":"2021","unstructured":"Kumar A, Swain CA, Shevde LA. Informing the new developments and future of cancer immunotherapy\u202f: future of cancer immunotherapy. Cancer Metastasis Rev. 2021;40:549\u201362.","journal-title":"Cancer Metastasis Rev"},{"key":"1383_CR5","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/annonc\/mdy335","volume":"29","author":"L Par\u00e9","year":"2018","unstructured":"Par\u00e9 L, Pascual T, Segu\u00ed E, Teixid\u00f3 C, Gonzalez-Cao M, Galv\u00e1n P, Rodr\u00edguez A, Gonz\u00e1lez B, Cuatrecasas M, Pineda E, Torn\u00e9 A, Crespo G, Martin-Algarra S, P\u00e9rez-Ruiz E, Reig \u00d2, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Mu\u00f1oz M, Victoria I, Ruiz G, Vi\u00f1olas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila M, Juan M, Llovet JM, Reguart N, Arance A, Prat A. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018;29:2121\u20138.","journal-title":"Ann Oncol"},{"key":"1383_CR6","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1128\/MCB.00159-15","volume":"35","author":"T Tsukiyama","year":"2015","unstructured":"Tsukiyama T, Fukui A, Terai S, Fujioka Y, Shinada K, Takahashi H, Yamaguchi TP, Ohba Y, Hatakeyama S. Molecular role of RNF43 in canonical and noncanonical Wnt signaling. Mol Cell Biol. 2015;35:2007\u201323.","journal-title":"Mol Cell Biol"},{"key":"1383_CR7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature11308","volume":"488","author":"BK Koo","year":"2012","unstructured":"Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM, Clevers H. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488:665\u20139.","journal-title":"Nature"},{"key":"1383_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13287-017-0548-8","volume":"8","author":"Y Gao","year":"2017","unstructured":"Gao Y, Cai A, Xi H, Li J, Xu W, Zhang Y, Zhang K, Cui J, Wu X, Wei B, Chen L. Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-beta\/catenin signaling pathway. Stem Cell Res Ther. 2017;8:98.","journal-title":"Stem Cell Res Ther"},{"key":"1383_CR9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2021.12.273","volume":"162","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dangol G, Okumura T, Roszik J, Rajapakshe K, Siemann M, Zaid M, Ghosh B, Monberg M, Guerrero PA, Singhi A, Haymaker CL, Clevers H, Abou-Elkacem L, Woermann SM, Maitra A. Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma. Gastroenterology. 2022;162:1303-1318.e1318.","journal-title":"Gastroenterology"},{"key":"1383_CR10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41467-021-27923-z","volume":"13","author":"G Belenguer","year":"2022","unstructured":"Belenguer G, Mastrogiovanni G, Pacini C, Hall Z, Dowbaj AM, Arnes-Benito R, Sljukic A, Prior N, Kakava S, Bradshaw CR, Davies S, Vacca M, Saeb-Parsy K, Koo BK, Huch M. RNF43\/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state. Nat Commun. 2022;13:334.","journal-title":"Nat Commun"},{"key":"1383_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108179","author":"DJ Flanagan","year":"2022","unstructured":"Flanagan DJ, Woodcock SA, Phillips C, Eagle C, Sansom OJ. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharmacol Ther. 2022. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108179.","journal-title":"Pharmacol Ther"},{"key":"1383_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/path.5868","volume":"257","author":"D Yamamoto","year":"2022","unstructured":"Yamamoto D, Oshima H, Wang D, Takeda H, Kita K, Lei X, Nakayama M, Murakami K, Ohama T, Takemura H, Toyota M, Suzuki H, Inaki N, Oshima M. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer. J Pathol. 2022;257:39\u201352.","journal-title":"J Pathol"},{"key":"1383_CR13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2021.12.273","volume":"162","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dangol G, Okumura T, Roszik J, Rajapakshe K, Siemann M, Zaid M, Ghosh B, Monberg M, Guerrero PA, Singhi A, Haymaker CL, Clevers H, Abou-Elkacem L, Woermann SM, Maitra A. Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma. Gastroenterology. 2022;162:1303-1318 e1318.","journal-title":"Gastroenterology"},{"key":"1383_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3892\/or.2013.2231","volume":"29","author":"N Matsushita","year":"2013","unstructured":"Matsushita N, Aruga A, Inoue Y, Kotera Y, Takeda K, Yamamoto M. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep. 2013;29:951\u20139.","journal-title":"Oncol Rep"},{"key":"1383_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1479-5876-12-63","volume":"12","author":"S Hazama","year":"2014","unstructured":"Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K, Shinozaki H, Kamiya A, Furukawa H, Oka M. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014;12:63.","journal-title":"J Transl Med"},{"key":"1383_CR16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1383_CR17","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"1383_CR18","doi-asserted-by":"crossref","first-page":"791962","DOI":"10.3389\/fonc.2022.791962","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang H, Yin H, Chen J, Yuan Y. An integrated pan-cancer analysis of 33 human cancers reveals the potential clinical implications and immunotherapeutic value of C-X-C motif chemokine ligand 13. Front Oncol. 2022;12:791962.","journal-title":"Front Oncol"},{"key":"1383_CR19","doi-asserted-by":"crossref","first-page":"844794","DOI":"10.3389\/fonc.2022.844794","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang S, Han S, Feng Y. Pan-cancer analysis based on EPOR expression with potential value in prognosis and tumor immunity in 33 tumors. Front Oncol. 2022;12:844794.","journal-title":"Front Oncol"},{"key":"1383_CR20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1159\/000430154","volume":"36","author":"L Niu","year":"2015","unstructured":"Niu L, Qin HZ, Xi HQ, Wei B, Xia SY, Chen L. RNF43 inhibits cancer cell proliferation and could be a potential prognostic factor for human gastric carcinoma. Cell Physiol Biochem. 2015;36:1835\u201346.","journal-title":"Cell Physiol Biochem"},{"key":"1383_CR21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ng.3127","volume":"46","author":"M Giannakis","year":"2014","unstructured":"Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, Garraway LA. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46:1264\u20136.","journal-title":"Nat Genet"},{"key":"1383_CR22","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.1073\/pnas.1307218110","volume":"110","author":"X Jiang","year":"2013","unstructured":"Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, Cong F. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:12649\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1383_CR23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12885-019-5880-1","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Sun L, Gao X, Guo A, Diao Y, Zhao Y. RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma. BMC Cancer. 2019;19:670.","journal-title":"BMC Cancer"},{"key":"1383_CR24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1089\/cmb.2019.0056","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wu W, Qu H. Integrated analysis of the gene expression changes during colorectal cancer progression by bioinformatic methods. J Comput Biol. 2019;26:1168\u201376.","journal-title":"J Comput Biol"},{"key":"1383_CR25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2019-320368","volume":"70","author":"M Zhang","year":"2021","unstructured":"Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, Ying X, Liu Y. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 2021;70:464\u201375.","journal-title":"Gut"},{"key":"1383_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"aadhe Cancer Genome Atlas Research Network","year":"2017","unstructured":"aadhe Cancer Genome Atlas Research Network. Electronic address, N. cancer genome atlas research, integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185-203 e113.","journal-title":"Cancer Cell"},{"key":"1383_CR27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, Chan KH, Chan AS, Tsui WY, Ho SL, Chan AK, Man JL, Foglizzo V, Ng MK, Chan AS, Ching YP, Cheng GH, Xie T, Fernandez J, Li VS, Clevers H, Rejto PA, Mao M, Leung SY. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573\u201382.","journal-title":"Nat Genet"},{"key":"1383_CR28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2015.12.027","volume":"52","author":"C Talabnin","year":"2016","unstructured":"Talabnin C, Janthavon P, Thongsom S, Suginta W, Talabnin K, Wongkham S. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma. Hum Pathol. 2016;52:47\u201354.","journal-title":"Hum Pathol"},{"key":"1383_CR29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.5098","volume":"245","author":"T Eto","year":"2018","unstructured":"Eto T, Miyake K, Nosho K, Ohmuraya M, Imamura Y, Arima K, Kanno S, Fu L, Kiyozumi Y, Izumi D, Sugihara H, Hiyoshi Y, Miyamoto Y, Sawayama H, Iwatsuki M, Baba Y, Yoshida N, Furukawa T, Araki K, Baba H, Ishimoto T. Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression. J Pathol. 2018;245:445\u201355.","journal-title":"J Pathol"},{"key":"1383_CR30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jcmgh.2020.11.005","volume":"11","author":"V Neumeyer","year":"2021","unstructured":"Neumeyer V, Brutau-Abia A, Allg\u00e4uer M, Pfarr N, Weichert W, Falkeis-Veits C, Kremmer E, Vieth M, Gerhard M, Mej\u00edas-Luque R. Loss of RNF43 function contributes to gastric carcinogenesis by impairing DNA damage response. Cell Mol Gastroenterol Hepatol. 2021;11:1071\u201394.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1383_CR31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2020;77:14\u201321.","journal-title":"Eur Urol"},{"key":"1383_CR32","doi-asserted-by":"crossref","first-page":"215581","DOI":"10.1016\/j.canlet.2022.215581","volume":"532","author":"C Miro","year":"2022","unstructured":"Miro C, Di Giovanni A, Murolo M, Cicatiello AG, Nappi A, Sagliocchi S, Di Cicco E, Morra F, Celetti A, Pacifico F, Imbimbo C, Crocetto F, Dentice M. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022;532:215581.","journal-title":"Cancer Lett"},{"key":"1383_CR33","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1158\/1078-0432.CCR-19-2303","volume":"26","author":"X Guan","year":"2020","unstructured":"Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Copy number loss of 17q22 Is associated with enzalutamide resistance and poor prognosis in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26:4616\u201324.","journal-title":"Clin Cancer Res"},{"key":"1383_CR34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2020.11.021","volume":"16","author":"D Pan","year":"2021","unstructured":"Pan D, Hu AY, Antonia SJ, Li CY. A gene mutation signature predicting immunotherapy benefits in patients with NSCLC. J Thorac Oncol. 2021;16:419\u201327.","journal-title":"J Thorac Oncol"},{"key":"1383_CR35","doi-asserted-by":"crossref","first-page":"e0242263","DOI":"10.1371\/journal.pone.0242263","volume":"15","author":"H Luo","year":"2020","unstructured":"Luo H, Ma C. Identification of prognostic genes in uveal melanoma microenvironment. PLoS ONE. 2020;15:e0242263.","journal-title":"PLoS ONE"},{"key":"1383_CR36","doi-asserted-by":"crossref","first-page":"114239","DOI":"10.1016\/j.addr.2022.114239","volume":"184","author":"S Arnouk","year":"2022","unstructured":"Arnouk S, De Groof TWM, Van Ginderachter JA. Imaging and therapeutic targeting of the tumor immune microenvironment with biologics. Adv Drug Deliv Rev. 2022;184:114239.","journal-title":"Adv Drug Deliv Rev"},{"key":"1383_CR37","doi-asserted-by":"crossref","first-page":"861525","DOI":"10.3389\/fimmu.2022.861525","volume":"13","author":"Y Guo","year":"2022","unstructured":"Guo Y, Yang J, Ren K, Tian X, Gao H, Tian X, Zhang X, Kan Q. The heterogeneity of immune cell infiltration landscape and its immunotherapeutic implications in hepatocellular carcinoma. Front Immunol. 2022;13:861525.","journal-title":"Front Immunol"},{"key":"1383_CR38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.2017.220","volume":"117","author":"TA Barnes","year":"2017","unstructured":"Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117:451\u201360.","journal-title":"Br J Cancer"},{"key":"1383_CR39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635\u201347.","journal-title":"Nat Rev Immunol"},{"key":"1383_CR40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","volume":"47","author":"M Melssen","year":"2017","unstructured":"Melssen M, Slingluff CL Jr. Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol. 2017;47:85\u201392.","journal-title":"Curr Opin Immunol"},{"key":"1383_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"1383_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-015-0109-9","volume":"13","author":"J Lu","year":"2016","unstructured":"Lu J, Chatterjee M, Schmid H, Beck S, Gawaz M. CXCL14 as an emerging immune and inflammatory modulator. J Inflamm. 2016;13:1.","journal-title":"J Inflamm"},{"key":"1383_CR43","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-21-2830","volume":"28","author":"A Kumar","year":"2022","unstructured":"Kumar A, Mohamed E, Tong S, Chen K, Mukherjee J, Lim Y, Wong CM, Boosalis Z, Shai A, Pieper RO, Gupta N, Perry A, Bollen AW, Molinaro AM, Solomon DA, Shieh JTC, Phillips JJ. CXCL14 promotes a robust brain tumor-associated immune response in glioma. Clin Cancer Res. 2022;28:2898\u2013910.","journal-title":"Clin Cancer Res"},{"key":"1383_CR44","doi-asserted-by":"crossref","first-page":"669474","DOI":"10.3389\/fimmu.2021.669474","volume":"12","author":"A Basu","year":"2021","unstructured":"Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy. Front Immunol. 2021;12:669474.","journal-title":"Front Immunol"},{"key":"1383_CR45","doi-asserted-by":"crossref","first-page":"713757","DOI":"10.3389\/fimmu.2021.713757","volume":"12","author":"R Chen","year":"2021","unstructured":"Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q. TNFSF13 is a novel onco-inflammatory marker and correlates with immune infiltration in gliomas. Front Immunol. 2021;12:713757.","journal-title":"Front Immunol"},{"key":"1383_CR46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ. A2AR adenosine signaling suppresses natural Killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78:1003\u201316.","journal-title":"Cancer Res"},{"key":"1383_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/cancers8060054","volume":"8","author":"HX Hao","year":"2016","unstructured":"Hao HX, Jiang X, Cong F. control of Wnt receptor turnover by R-spondin-ZNRF3\/RNF43 signaling module and Its dysregulation in cancer. Cancers. 2016;8:54.","journal-title":"Cancers"},{"key":"1383_CR48","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/0008-5472.CAN-20-0957","volume":"80","author":"J Yu","year":"2020","unstructured":"Yu J, Yusoff PAM, Woutersen DTJ, Goh P, Harmston N, Smits R, Epstein DM, Virshup DM, Madan B. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 2020;80:5619\u201332.","journal-title":"Cancer Res"},{"key":"1383_CR49","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22:12808.","journal-title":"Int J Mol Sci"},{"key":"1383_CR50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","volume":"36","author":"CE Steuer","year":"2018","unstructured":"Steuer CE, Ramalingam SS. Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol. 2018;36:631\u20132.","journal-title":"J Clin Oncol"},{"key":"1383_CR51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D\u2019Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136.","journal-title":"Nat Genet"},{"key":"1383_CR52","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"1383_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-1086-5","volume":"20","author":"K Li","year":"2020","unstructured":"Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:1\u20133.","journal-title":"Cancer Cell Int"},{"key":"1383_CR54","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-21-3018","volume":"28","author":"A Seeber","year":"2022","unstructured":"Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ. Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer. Clin Cancer Res. 2022;28:1863\u201370.","journal-title":"Clin Cancer Res"},{"key":"1383_CR55","doi-asserted-by":"crossref","first-page":"105684","DOI":"10.1016\/j.phrs.2021.105684","volume":"169","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu R, Wang W, Wang C, Zhang N, Shao X, He Q, Ying M. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res. 2021;169:105684.","journal-title":"Pharmacol Res"},{"key":"1383_CR56","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395:1078\u201388.","journal-title":"Lancet"},{"key":"1383_CR57","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530.","journal-title":"Cancer Treat Rev"},{"key":"1383_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65759","author":"T Radaszkiewicz","year":"2021","unstructured":"Radaszkiewicz T, Noskova M, Gomoryova K, Vondalova Blanarova O, Radaszkiewicz KA, Pickova M, Vichova R, Gybel T, Kaiser K, Demkova L, Kucerova L, Barta T, Potesil D, Zdrahal Z, Soucek K, Bryja V. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.65759.","journal-title":"Elife"},{"key":"1383_CR59","doi-asserted-by":"publisher","DOI":"10.3727\/096504021X16252201000833","author":"D Zhu","year":"2021","unstructured":"Zhu D, Zhang L, Shi X, Gao S, Yue C, Zhang L, Bai Y, Wang Q, Okada A, Yasui T, Wang C, Cui X, Zuo L. RNF43 is a novel tumor suppressor and prognostic indicator in clear cell renal cell carcinoma. Oncol Res. 2021. https:\/\/doi.org\/10.3727\/096504021X16252201000833.","journal-title":"Oncol Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01383-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:07:54Z","timestamp":1700489274000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01383-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01383-1","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Second Xiangya Hospital (ID:2022499). The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"438"}}